The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.
The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both ...
The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an ...
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.
Daewoong Pharmaceutical officially launched its botulinum toxin (botox) product 'Nabota' in Saudi Arabia on the 31st.
Celltrion, a major South Korean biopharmaceutical firm, on Friday said its new biosimilar for an autoimmune disease treatment has received approval from the US Food and Drug Administration (FDA). The ...
Celltrion's biosimilar Avtozma, used to treat inflammatory diseases, was approved for the U.S. market by the Food and Drug Administration.
The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.
January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...
JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...